Search

Your search keyword '"Anderson, Tara C."' showing total 30 results
Start Over Author "Anderson, Tara C." Publication Year Range Last 10 years
30 results on '"Anderson, Tara C."'

3. Persons Evaluated for 2019 Novel Coronavirus — United States, January 2020

Author

2019-nCoV Persons Under Investigation Team, Bajema, Kristina L., Oster, Alexandra M., McGovern, Olivia L., Lindstrom, Stephen, Stenger, Mark R., Anderson, Tara C., Isenhour, Cheryl, Clarke, Kevin R., Evans, Mary E., Chu, Victoria T., Biggs, Holly M., Kirking, Hannah L., Gerber, Susan I., Hall, Aron J., Fry, Alicia M., and Oliver, Sara E.

Published
2020

4. Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged [greater than or equal to] 18 years--United States, July 2022

Author

Twentyman, Evelyn, Wallace, Megan, Roper, Lauren E., Anderson, Tara C., Rubis, Amy B., Fleming-Dutra, Katherine E., Hall, Elisha, Hsu, Joy, Rosenblum, Hannah G., Godfrey, Monica, Archer, W. Roodly, Moulia, Danielle L., Daniel, Laura, Brooks, Oliver, Talbot, H. Keipp, Lee, Grace M., Bell, Beth P., Daley, Matthew, Meyer, Sarah, and Oliver, Sara E.

Subjects
United States. Food and Drug Administration, United States. Department of Health and Human Services, Vaccines -- Usage, Health
Abstract

The NVX-CoV2373 (Novavax) COVID-19 vaccine is a recombinant spike (rS) protein nanoparticle vaccine with Matrix-M adjuvant to protect against infection with SARS-CoV-2, the virus that causes COVID-19. On July 13, [...]

Published
2022

5. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years--United States, June 2022

Author

Fleming-Dutra, Katherine E., Wallace, Megan, Moulia, Danielle L., Twentyman, Evelyn, Roper, Lauren E., Hall, Elisha, Link-Gelles, Ruth, Godfrey, Monica, Woodworth, Kate R., Anderson, Tara C., Rubis, Amy B., Shanley, Edwin, III, Jones, Jefferson M., Morgan, Rebecca L., Brooks, Oliver, Talbot, H. Keipp, Lee, Grace M., Bell, Beth P., Daley, Matthew, Meyer, Sarah, and Oliver, Sara E.

Subjects
United States. Food and Drug Administration, United States. Department of Health and Human Services, Pfizer Inc., Children's furniture -- Usage, Vaccines -- Usage, Pharmaceutical industry -- Usage, Health
Abstract

On June 28, 2022, this report was posted as an MMWR Early Release on the MMWR website (https://www.cdc.gov/mmwr). On June 17, 2022, the Food and Drug Administration (FDA) issued Emergency [...]

Published
2022

9. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged [greater than or equal to] 19 Years: Recommendations of the Advisory Committee on Immunization Practices--United States, 2022

Author

Anderson, Tara C., Masters, Nina B., Guo, Angela, Shepersky, Leah, Leidner, Andrew J., Lee, Grace M., Kotton, Camille N., and Dooling, Kathleen L.

Subjects
United States. Food and Drug Administration, Shingles (Disease) -- Prevention, Adults -- Usage, Vaccines -- Usage, Health
Abstract

Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline [GSK]) is a 2-dose (0.5 mL each) subunit vaccine containing recombinant glycoprotein E in combination with adjuvant ([AS01.sub.B]) that was licensed in the United [...]

Published
2022

14. Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged ≥18 years — United States, July 2022

Author

Twentyman, Evelyn, primary, Wallace, Megan, additional, Roper, Lauren E., additional, Anderson, Tara C., additional, Rubis, Amy B., additional, Fleming-Dutra, Katherine E., additional, Hall, Elisha, additional, Hsu, Joy, additional, Rosenblum, Hannah G., additional, Godfrey, Monica, additional, Archer, W. Roodly, additional, Moulia, Danielle L., additional, Daniel, Laura, additional, Brooks, Oliver, additional, Talbot, H. Keipp, additional, Lee, Grace M., additional, Bell, Beth P., additional, Daley, Matthew, additional, Meyer, Sarah, additional, and Oliver, Sara E., additional

Published
2022
Full Text
View/download PDF

15. Outbreaks of human Salmonella infections associated with live poultry, United States, 1990-2014

Author

Basler, Colin, Nguyen, Thai-An, Anderson, Tara C., Hancock, Thane, and Behravesh, Casey Barton

Subjects
United States. Department of Agriculture, United States. Centers for Disease Control and Prevention, Salmonella food poisoning -- Prevention, Poultry industry, Infection -- Prevention, Epidemiology, Salmonella, Health
Abstract

Cialmonella species are zoonotic bacteria found in the O intestinal tract of many animals, including cattle, pigs, horses, other mammals, reptiles, amphibians, and poultry (e.g., chickens, ducks, geese, and turkeys) [...]

Published
2016
Full Text
View/download PDF

17. Survey of Physician Practices, Attitudes, and Knowledge Regarding Recombinant Zoster Vaccine

Author

Hurley, Laura P., primary, O’Leary, Sean T., additional, Dooling, Kathleen, additional, Anderson, Tara C., additional, Crane, Lori A., additional, Cataldi, Jessica R., additional, Brtnikova, Michaela, additional, Beaty, Brenda L., additional, Gorman, Carol, additional, Guo, Angela, additional, Lindley, Megan C., additional, and Kempe, Allison, additional

Published
2022
Full Text
View/download PDF

20. Persons Evaluated for 2019 Novel Coronavirus — United States, January 2020

Author

Bajema, Kristina L., Oster, Alexandra M., McGovern, Olivia L., Lindstrom, Stephen, Stenger, Mark R., Anderson, Tara C., Isenhour, Cheryl, Clarke, Kevin R., Evans, Mary E., Chu, Victoria T., Biggs, Holly M., Kirking, Hannah L., Gerber, Susan I., Hall, Aron J., Fry, Alicia M., Oliver, Sara E., Abedi, Glen, Bower, William, Chatham-Stephens, Kevin, Conklin, Laura, Cooley, Laura, Cortese, Margaret, Curns, Aaron, Dooling, Kathleen, Gokhale, Runa, Gold, Jeremy, Grant, Gavin, Gutman, Julie, Hesse, Elisabeth, Kamili, Shifaq, Kim, Lindsay, Kirkcaldy, Robert, Koumans, Emily, Kujawski, Stephanie, Langley, Gayle, Lively, Joana, Lu, Xiaoyan, Lynch, Brian, Lyss, Sheryl, Malapati, Lakshmi, Martin, Michael, Mbaeyi, Sarah, McClung, Paul, Midgley, Claire, Miller, Maureen, Morales, Michelle, Murray, Janna', Parker Fiebelkorn, Amy, Patel, Manisha, Peacock, Georgina, Pierce, Taran, Rha, Brian, Sakthivel, Senthilkumar, Schneider, Eileen, Siegel, David A., Sunshine, Brittany, Wallace, Megan, Wang, Lijuan, Watson, John, Whitaker, Brett, and Yousaf, Anna

Subjects
Adult, Male, medicine.medical_specialty, Health (social science), Adolescent, Epidemiology, Health, Toxicology and Mutagenesis, Pneumonia, Viral, Disease cluster, 01 natural sciences, Risk Assessment, Disease Outbreaks, Health(social science), 03 medical and health sciences, Betacoronavirus, Young Adult, 0302 clinical medicine, Health Information Management, Health care, Pandemic, medicine, Infection control, Humans, Mass Screening, 030212 general & internal medicine, Full Report, 0101 mathematics, Child, Pandemics, Mass screening, Aged, business.industry, SARS-CoV-2, Public health, 010102 general mathematics, COVID-19, General Medicine, Middle Aged, United States, Family medicine, Child, Preschool, Female, Centers for Disease Control and Prevention, U.S, Contact Tracing, business, Risk assessment, Coronavirus Infections, Travel-Related Illness, Contact tracing
Abstract

In December 2019, a cluster of cases of pneumonia emerged in Wuhan City in central China's Hubei Province. Genetic sequencing of isolates obtained from patients with pneumonia identified a novel coronavirus (2019-nCoV) as the etiology (1). As of February 4, 2020, approximately 20,000 confirmed cases had been identified in China and an additional 159 confirmed cases in 23 other countries, including 11 in the United States (2,3). On January 17, CDC and the U.S. Department of Homeland Security's Customs and Border Protection began health screenings at U.S. airports to identify ill travelers returning from Wuhan City (4). CDC activated its Emergency Operations Center on January 21 and formalized a process for inquiries regarding persons suspected of having 2019-nCoV infection (2). As of January 31, 2020, CDC had responded to clinical inquiries from public health officials and health care providers to assist in evaluating approximately 650 persons thought to be at risk for 2019-nCoV infection. Guided by CDC criteria for the evaluation of persons under investigation (PUIs) (5), 210 symptomatic persons were tested for 2019-nCoV; among these persons, 148 (70%) had travel-related risk only, 42 (20%) had close contact with an ill laboratory-confirmed 2019-nCoV patient or PUI, and 18 (9%) had both travel- and contact-related risks. Eleven of these persons had laboratory-confirmed 2019-nCoV infection. Recognizing persons at risk for 2019-nCoV is critical to identifying cases and preventing further transmission. Health care providers should remain vigilant and adhere to recommended infection prevention and control practices when evaluating patients for possible 2019-nCoV infection (6). Providers should consult with their local and state health departments when assessing not only ill travelers from 2019-nCoV-affected countries but also ill persons who have been in close contact with patients with laboratory-confirmed 2019-nCoV infection in the United States.

Published
2020
Full Text
View/download PDF

23. Demographic, clinical, and epidemiologic characteristics of persons under investigation for Coronavirus Disease 2019—United States, January 17–February 29, 2020

Author

McGovern, Olivia L., primary, Stenger, Mark, additional, Oliver, Sara E., additional, Anderson, Tara C., additional, Isenhour, Cheryl, additional, Mauldin, Matthew R., additional, Williams, Nia, additional, Griggs, Eric, additional, Bogere, Tonny, additional, Edens, Chris, additional, Curns, Aaron T., additional, Lively, Joana Y., additional, Zhou, Yingtao, additional, Xu, Songli, additional, Diaz, Maureen H., additional, Waller, Jessica L., additional, Clarke, Kevin R., additional, Evans, Mary E., additional, Hesse, Elisabeth M., additional, Morris, Sapna Bamrah, additional, McClung, Robert P., additional, Cooley, Laura A., additional, Logan, Naeemah, additional, Boyd, Andrew T., additional, Taylor, Allan W., additional, Bajema, Kristina L., additional, Lindstrom, Stephen, additional, Elkins, Christopher A., additional, Jones, Christopher, additional, Hall, Aron J., additional, Graitcer, Samuel, additional, Oster, Alexandra M., additional, Fry, Alicia M., additional, Fischer, Marc, additional, Conklin, Laura, additional, and Gokhale, Runa H., additional

Published
2021
Full Text
View/download PDF

24. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.

Author

Anderson, Tara C., Masters, Nina B., Guo, Angela, Shepersky, Leah, Leidner, Andrew J., Lee, Grace M., Kotton, Camille N., and Dooling, Kathleen L.

Subjects
*IMMUNIZATION, *GLYCOPROTEINS, *IMMUNOCOMPROMISED patients
Abstract

Zoster Vaccine Recombinant, Adjuvanted (Shingrix, GlaxoSmithKline [GSK]) is a 2-dose (0.5 mL each) subunit vaccine containing recombinant glycoprotein E in combination with adjuvant (AS01B) that was licensed in the United States for prevention of herpes zoster for adults aged ≥50 years by the Food and Drug Administration (FDA) and recommended for immunocompetent adults aged ≥50 years by the Advisory Committee on Immunization Practices (ACIP) in 2017* (1). On July 23, 2021, the FDA expanded the indication for recombinant zoster vaccine (RZV) to include adults aged ≥18 years who are or will be at increased risk for herpes zoster because of immunodeficiency or immunosuppression caused by known disease or therapy (2). On October 20, 2021, ACIP recommended 2 doses of RZV for the prevention of herpes zoster and related complications in adults aged ≥19 years† who are or will be immunodeficient or immunosuppressed because of disease or therapy. RZV is the first herpes zoster vaccine approved for use in immunocompromised persons. With moderate to high vaccine efficacy and an acceptable safety profile, RZV has the potential to prevent considerable herpes zoster incidence and related complications. This report updates previous ACIP recommendations for the prevention of herpes zoster (1,3). [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

26. Multistate outbreak of human Salmonella Typhimurium infections linked to live poultry from agricultural feed stores and mail-order hatcheries, United States 2013

Author

Anderson, Tara C., primary, Nguyen, Thai-An, additional, Adams, Jennifer K., additional, Garrett, Nancy M., additional, Bopp, Cheryl A., additional, Baker, Joe B., additional, McNeil, Carrie, additional, Torres, Paul, additional, Ettestad, Paul J., additional, Erdman, Matthew M., additional, Brinson, Denise L., additional, Gomez, Thomas M., additional, and Barton Behravesh, Casey, additional

Published
2016
Full Text
View/download PDF

28. Outbreaks of Salmonellosis From Small Turtles

Author

Walters, Maroya Spalding, primary, Simmons, Latoya, additional, Anderson, Tara C., additional, DeMent, Jamie, additional, Van Zile, Kathleen, additional, Matthias, Laura P., additional, Etheridge, Sonia, additional, Baker, Ronald, additional, Healan, Cheryl, additional, Bagby, Rita, additional, Reporter, Roshan, additional, Kimura, Akiko, additional, Harrison, Cassandra, additional, Ajileye, Kadri, additional, Borders, Julie, additional, Crocker, Kia, additional, Smee, Aaron, additional, Adams-Cameron, Meg, additional, Joseph, Lavin A., additional, Tolar, Beth, additional, Trees, Eija, additional, Sabol, Ashley, additional, Garrett, Nancy, additional, Bopp, Cheryl, additional, Bosch, Stacey, additional, and Behravesh, Casey Barton, additional

Published
2016
Full Text
View/download PDF

30. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022.

Author

Fleming-Dutra KE, Wallace M, Moulia DL, Twentyman E, Roper LE, Hall E, Link-Gelles R, Godfrey M, Woodworth KR, Anderson TC, Rubis AB, Shanley E 3rd, Jones JM, Morgan RL, Brooks O, Talbot HK, Lee GM, Bell BP, Daley M, Meyer S, and Oliver SE

Subjects
2019-nCoV Vaccine mRNA-1273, Advisory Committees, BNT162 Vaccine, Child, Child, Preschool, Humans, Immunization, SARS-CoV-2, United States epidemiology, Vaccination, Young Adult, COVID-19 epidemiology, COVID-19 prevention & control, COVID-19 Vaccines
Abstract

On June 17, 2022, the Food and Drug Administration (FDA) issued Emergency Use Authorization (EUA) amendments for the mRNA-1273 (Moderna) COVID-19 vaccine for use in children aged 6 months-5 years, administered as 2 doses (25 µg [0.25 mL] each), 4 weeks apart, and BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine for use in children aged 6 months-4 years, administered as 3 doses (3 µg [0.2 mL] each), at intervals of 3 weeks between doses 1 and 2 and ≥8 weeks between doses 2 and 3. On June 18, 2022, the Advisory Committee on Immunization Practices (ACIP) issued separate interim recommendations for use of the Moderna COVID-19 vaccine in children aged 6 months-5 years and the Pfizer-BioNTech COVID-19 vaccine in children aged 6 months-4 years for the prevention of COVID-19.* Both the Moderna and Pfizer-BioNTech COVID-19 vaccines met the criteria for immunobridging, which is the comparison of neutralizing antibody levels postvaccination in young children with those in young adults in whom efficacy had been demonstrated. Descriptive efficacy analyses were also conducted for both Moderna and Pfizer-BioNTech COVID-19 vaccines during the period when the Omicron variant of SARS-CoV-2 (the virus that causes COVID-19) predominated. No specific safety concerns were identified among recipients of either vaccine. ACIP recommendations for the use of the Moderna COVID-19 vaccine and the Pfizer-BioNTech COVID-19 vaccine in children aged 6 months-5 years and 6 months-4 years, respectively, are interim and will be updated as additional information becomes available. Vaccination is important for protecting children aged 6 months-5 years against COVID-19., Competing Interests: All authors have completed and submitted the International Committee of Medical Journal Editors form for disclosure of potential conflicts of interest. No potential conflicts of interest were disclosed.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results